Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus

Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus

Beginning in May 2022, a novel cluster of monkeypox virus infections was detected in humans. This virus has spread rapidly to non-endemic countries, sparking global concern. Specific vaccines based on the vaccinia virus (VACV) have demonstrated high efficacy against monkeypox viruses in the past and...

Full description

Bibliographic Details
Main Authors: Syed Faraz Ahmed, Muhammad Saqib Sohail, Ahmed Abdul Quadeer, Matthew R. McKay
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Viruses
Subjects:
monkeypox
vaccinia virus
vaccines
immunity
genetic similarity
T cells
Online Access:https://www.mdpi.com/1999-4915/14/9/1960

Similar Items

Similar Items